The global clot busting drugs market is estimated to reach a market value of around US$ 28.8 Billion in 2022, with the global market estimated to surge ahead at a CAGR value of 7.3% to reach a valuation of US$ 58.4 Billion by the end of 2032. The injectable route of administration is driving the global clot busting drugs market as of 2021.
Market Outlook:
|
Data |
Market Insight |
|---|---|
|
Estimated market Value 2022 |
US$ 28.8 Billion |
|
Estimated market Value 2032 |
US$ 58.4 Billion |
|
CAGR of 2022 to 2032 |
7.3 % |
|
Market share of Top 5 countries |
57.4 % |
|
Key Market players |
Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh., Genentech Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., The Medicines Company, Pfizer Inc. |
Abnormal blood clots are broken by clot-busting drugs. In the human body, a blood clot is a highly common and dangerous problem. A blood clot can obstruct veins and arteries, which can result in a hemorrhage, a stroke, or a heart attack. Clot-busting drugs work by breaking up aberrant blood clots and preserving regular blood flow.
Drugs that dissolve blood clots quickly help prevent many strokes. Clot-busting drugs can lessen the amount of brain damage that can result from a stroke by unblocking a clogged blood artery and restoring blood flow. Clot-busting medications must be administered within a few hours of the onset of stroke symptoms in order to be helpful.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The overall, clot busting drugs market sales account for approximately 17.3% of revenue share in the global cardiovascular drugs market, which was valued at around US$ 155.6 Billion in 2021.
The global market for clot busting drugs recorded a historic CAGR of 7.3% in the last five years from 2016 to 2021.
The global market for clot busting drugs will be supported globally over the forecast period by the growing need for pharmaceuticals to treat heart attacks and strokes promptly. The development of clot busting therapeutic options and improvements in the pharmaceutical sector will further boost the growth of the global market for clot busting drugs.
Furthermore, as cardiovascular disorders like heart attacks and strokes become more common, the demand for clot busting drugs is anticipated to rise. The fifth most common cause of death in the USA is a stroke. The rising frequency of strokes needs an immediate response, and clot buster drugs can assist by dissolving the blood clot accumulating in the veins, which reduces blood pressure. Strokes are increasing the rate of death in the population, which is causing the market for clot busting drugs to expand globally. Additionally, during the course of the forecast period, the increased risk of ischemic stroke in the global population is anticipated to boost the global market for clot busting drugs.
Additionally, stroke is the second leading cause of mortality worldwide, accounting for an estimated 5.5 million fatalities annually. Along with the enormous morbidity caused by stroke, which results in up to 50% of survivors having a long-term disability, there is also a significant mortality rate. As a result, stroke is a condition that is very important to public health and has major economic and social repercussions. The global health impact of a stroke is expected to rise in the next years, especially in developing countries, which will boost the need for clot-busting drugs.
The cost of clot busting drugs that have shown to be particularly effective in treating ischemic stroke patients has more than doubled, considerably outpacing any Medicare/Medicaid reimbursements to hospitals that employ the medication. Over the previous ten years, the price of alteplase (a clot busting drug) has climbed by 111%. According to Cardiovascular Business, the drug is particularly helpful in treating patients' acute ischemic stroke symptoms. If taken during the first few hours of a stroke, the medicine can frequently completely reverse its effects.
The global clot busting drugs market is thus likely to show high growth over the coming years a CAGR value of 7.3% and reach a global market size of US$ 58.4 Billion by 2032.
During the projected period, there will be an increase in demand for pharmaceuticals to quickly treat heart attacks and strokes, which will lead to growth in the global market for clot-busting drugs. Developments in the pharmaceutical sector and the creation of clot-busting therapy options both influence the market's potential future expansion.
Tenecteplase, a newer generation clot busting medicine, outperforms the standard treatment for ischemic strokes in a number of critical areas, including improved health outcomes and lower costs, according to research that was conducted by the American Stroke Association.
The market for clot busting drugs will experience growth globally during the forecast period due to the increasing need for pharmaceutical products to promptly treat heart attacks and strokes. For instance, non-fibrin-specific medications include plasminogen activating complex, streptokinase, and urokinase. Blood coagulation in the lungs is treated with urokinase, a drug of the serine protease class. Myocardial infarction, pulmonary embolism, and arterial thromboembolism are all conditions that are treated using the thrombolytic drug streptokinase.
The introduction of these innovative and better alternatives is expected to create a lucrative market for drug manufacturers and increase the adoption rate of their products, which will drive the Clot Busting drugs market in the projected period.
Principal Consultant
Drugs that target fibrin are fibrinolysis-inducing substances with negligible lytic effects, yet in stroke situations, they function as blood thinners. Tissue plasminogen activator (tPA), one of these medications, initiates the blood clots' disintegration when a stroked state is present. The medication is exceedingly risky and should only be used under medical supervision due to the potential side effects of brain damage, paralysis, or even impaired speech. The tPA raises the likelihood of bleeding, it may not be possible for patients with a history of bleeding problems, recent operations, unstable blood pressure, or a recent severe concussion to get it.
A safe dose of the drug, which is administered intravenously, frequently does not remain in the bloodstream long enough to dissolve the large clots, and increasing the dose increases the risk of bleeding even though it is effective against smaller clots in thinner capillaries.
Additional adverse effects of these clot busting medications include bleeding from wounds or the area where the drug was shot, an allergic response, fever, reduced blood pressure, and signs of bleeding from other parts of the body, such as nosebleeds, black tarry stools, blood in the urine, and gum bleeding.
The aforementioned factors can serve as potential barriers to the expansion of the clot busting drugs market in the future.
The USA has dominated the North American region by reaching a worth of US$ 8.4 Billion while withholding the vast majority of the worldwide market share of roughly 31.1% in 2021. Nearly 8 lac strokes occur each year in the USA blood clot that blocks a vein supplying blood to the brain causes more than 85% of these strokes to be ischemic. The USA is anticipated to grow during the projected period for the same reason.
As of 2021, Germany has led the European clot busting drugs market withholding about 7.6% of the global market share. In Germany, between 30 to 40% of adults have excessive blood pressure. With age, the percentage rises. Every second individual is impacted starting around age 60. It may result in deadly outcomes such as cardiac arrhythmias, renal failure, a stroke, or a heart attack. With a growing number of drug manufacturers for the conditions like stroke and an increasing pipeline of clot busting drugs, Germany clot busting drugs market is expected to show substantial growth over the projected period.
China accounted for US$ 1.6 Billion withholding the majority of the East Asian market share as of 2021. With an aging population, China has made significant progress in reforming its healthcare system. It currently offers a basic kind of universal health insurance and generously subsidizes an expanding list of essential medications.
In an effort to make medicines, including certain products from Pfizer, GlaxoSmithKline, and Novartis, more affordable, China is expected to reduce the prices of roughly 400 drugs for respiratory disorders, fever, cardiovascular diseases, and pain by up to 20%. This is expected to boost the market for clot busting drugs in the future too within this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, anticoagulants have driven the global market by achieving a valuation of about US$ 9.9 Billion in 2021 withholding the majority of the global market share of about 36.7%. Due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced. Emerging nations are increasingly using novel oral anticoagulants (NOACs) and over the forecast period, increasing product launches and approvals are anticipated to support market expansion.
For instance, Natco Pharma introduced a rivaroxaban molecule under the trade name RPIGAT in December 2020. This anticoagulant drug is used to treat and prevent blood clots.
By indication, pulmonary embolism has led the global market by achieving a valuation of US$ 8.4 Billion by the end of 2021. The demand for clot busting drugs is expected to increase because those who are receiving chemotherapy or who have a family history of pulmonary embolism are most at risk. The market is expected to thrive as the number of cancer patients increases.
In 2020, cancer was responsible for around 10 million deaths, according to the World Health Organization. Additionally, it is projected that rising government investments to enhance public healthcare systems will accelerate market expansion.
The injectable dominated the market in terms of route of administration and is predicted to continue expanding, accounting for more than half of the global market. The primary factors driving the growth of this market are the increasing use of biological drugs, the number of chronic diseases, the surge in sharps injuries, and the benefits of injectables. These problems have raised the demand for devices like safety syringes, prefilled syringes, and auto-injectors.
By distribution channel, hospital pharmacies have led the global market by generating nearly one-third of the global revenue as of 2021. The growing incidence of chronic diseases, patient compliance, and the wide & easy availability of a variety of products within the hospital premises are all responsible for the high percentage of this segment.
Tissue plasminogen activator (tPA) and thrombolytic drugs have changed how heart attack patients are treated, and they have sparked competition among pharmaceutical companies. In order to introduce new technologies and therapies, major companies in the global market for clot busting drugs are investing in research and development operations. To acquire a competitive edge, several of the other companies want to get product approvals for their new items. For example,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2016 to 2021 |
| Market Analysis | US$ Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Rest of Latin America, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Australia, New Zealand, Turkey, GCC, South Africa, Israel, North Africa and Rest of MEA. |
| Key Market Segments Covered | Product, Indication, Route of Administration Distribution Channel and Regions. |
| Key Companies Profiled | Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh., Genentech Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., The Medicines Company, Pfizer Inc. |
| Pricing | Available upon Request |
The global clot busting drugs market is estimated to be worth US$ 26.9 Billion at end of 2021.
The clot busting drugs market is expected to reach US$ 58.4 Billion by end of 2032 growing at a CAGR of 7.3%.
Molecular and biological developments in clot busting drugs, new product approvals and launches, and increasing sedentary lifestyles among people leading to an increase in the prevalence of cardiovascular diseases are some of the key factors that drive this market.
The North American region has the highest market share of about 32.4% by the end of 2021 in the global clot busting drugs market.
South Asia is estimated to grow with a CAGR rate of 6.0% in the forecast duration of the global clot busting drugs market.
The USA, China, Germany, Japan, and the United Kingdom are the top five countries, which are expected to drive demand in the clot busting drugs market.
Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh., Genentech Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., The Medicines Company, Pfizer Inc. are some of the key players in the clot busting drug industry.
From 2016 to 2021, the market for clot busting drugs expanded at the rate of 7.3%.
China accounted for 6.1% of the market share at the end of 2021 in the global market.
The United Kingdom displayed a market share of around 7.6% in 2021 in the global clot busting drugs market
1. Executive Summary | Clot Busting Drugs Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, by Region
4.2. Key promotional strategies by manufacturers
4.3. Regulatory Landscape
4.4. Value chain analysis
4.5. Product adoption analysis
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Increasing Complexity of Healthcare Operations
5.2.3. Product Pricing
5.2.4. Product & Stock Availability
5.2.5. Rising Prevalence of Cardio-Vascular Diseases and Surgical Procedures
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Indication
6.1.3. By Route of Administration
6.1.4. By Distribution Channel
6.1.5. By Country
6.2. 2021 Market Scenario
7. Global Demand (in Value or Distribution Channel in US$ Billion) Analysis 2016 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Billion) Analysis, 2016 to 2021
7.2. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Billion) Analysis, by Product, 2016 to 2021
8.3. Current and Future Market Size (US$ Billion) Analysis and Forecast, by Product, 2022 to 2032
8.3.1. Thrombolytic Drugs
8.3.2. Anti-Platelet Drugs
8.3.3. Anticoagulants
8.3.4. Others
8.4. Market Attractiveness Analysis, by Product
9. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Billion) Analysis, by Indication, 2016 to 2021
9.3. Current and Future Market Size (US$ Billion) Analysis and Forecast, by Indication, 2022 to 2032
9.3.1. Pulmonary Embolism
9.3.2. Deep Vein Thrombosis
9.3.3. Atrial Fibrillation
9.3.4. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Billion) Analysis, By Route of Administration, 2016 to 2021
10.3. Current and Future Market Size (US$ Billion) Analysis and Forecast, by Route of Administration, 2022 to 2032
10.3.1. Oral
10.3.2. Injectable
10.4. Market Attractiveness Analysis, by Route of Administration
11. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Billion) Analysis, By Distribution Channel, 2016 to 2021
11.3. Current and Future Market Size (US$ Billion) Analysis and Forecast, by Distribution Channel, 2022 to 2032
11.3.1. Hospital Pharmacy
11.3.2. Drug Store
11.3.3. Online Pharmacy
11.3.4. Retail Pharmacies
11.4. Market Attractiveness Analysis, by Distribution Channel
12. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Billion) Analysis, by Region, 2016 to 2021
12.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis, by Region
13. North America Analysis 2016 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Historical Market Size (US$ Billion) Analysis Trend Analysis, by Market Taxonomy, 2016 to 2021
13.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Indication
13.4.4. By Route of Administration
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Country-Level Analysis & Forecast
13.7.1. USA Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast, by Market Taxonomy
13.7.1.2.1. By Product
13.7.1.2.2. By Indication
13.7.1.2.3. By Route of Administration
13.7.1.2.4. By Distribution Channel
13.7.2. Canada Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast, by Market Taxonomy
13.7.2.2.1. By Product
13.7.2.2.2. By Indication
13.7.2.2.3. By Route of Administration
13.7.2.2.4. By Distribution Channel
14. Latin America Analysis 2016 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Billion) Analysis Trend Analysis, by Market Taxonomy, 2016 to 2021
14.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Indication
14.4.4. By Route of Administration
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country-Level Analysis & Forecast
14.7.1. Mexico Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast, by Market Taxonomy
14.7.1.2.1. By Product
14.7.1.2.2. By Indication
14.7.1.2.3. By Route of Administration
14.7.1.2.4. By Distribution Channel
14.7.2. Brazil Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast, by Market Taxonomy
14.7.2.2.1. By Product
14.7.2.2.2. By Indication
14.7.2.2.3. By Route of Administration
14.7.2.2.4. By Distribution Channel
14.7.3. Argentina Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast, by Market Taxonomy
14.7.3.2.1. By Product
14.7.3.2.2. By Indication
14.7.3.2.3. By Route of Administration
14.7.3.2.4. By Distribution Channel
15. Europe Analysis 2016 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Billion) Analysis Trend Analysis, by Market Taxonomy, 2016 to 2021
15.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Product
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Indication
15.4.4. By Route of Administration
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. Germany Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast, by Market Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By Indication
15.7.1.2.3. By Route of Administration
15.7.1.2.4. By Distribution Channel
15.7.2. Italy Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast, by Market Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By Indication
15.7.2.2.3. By Route of Administration
15.7.2.2.4. By Distribution Channel
15.7.3. France Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast, by Market Taxonomy
15.7.3.2.1. By Product
15.7.3.2.2. By Indication
15.7.3.2.3. By Route of Administration
15.7.3.2.4. By Distribution Channel
15.7.4. United Kingdom Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast, by Market Taxonomy
15.7.4.2.1. By Product
15.7.4.2.2. By Indication
15.7.4.2.3. By Route of Administration
15.7.4.2.4. By Distribution Channel
15.7.5. Spain Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast, by Market Taxonomy
15.7.5.2.1. By Product
15.7.5.2.2. By Indication
15.7.5.2.3. By Route of Administration
15.7.5.2.4. By Distribution Channel
15.7.6. BENELUX Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast, by Market Taxonomy
15.7.6.2.1. By Product
15.7.6.2.2. By Indication
15.7.6.2.3. By Route of Administration
15.7.6.2.4. By Distribution Channel
15.7.7. Russia Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast, by Market Taxonomy
15.7.7.2.1. By Product
15.7.7.2.2. By Indication
15.7.7.2.3. By Route of Administration
15.7.7.2.4. By Distribution Channel
16. East Asia Analysis 2016 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Distribution Channel (US$ Billion) Analysis Trend Analysis, by Market Taxonomy, 2016 to 2021
16.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Product
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Indication
16.4.4. By Route of Administration
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. China Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast, by Market Taxonomy
16.7.1.2.1. By Product
16.7.1.2.2. By Indication
16.7.1.2.3. By Route of Administration
16.7.1.2.4. By Distribution Channel
16.7.2. Japan Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast, by Market Taxonomy
16.7.2.2.1. By Product
16.7.2.2.2. By Indication
16.7.2.2.3. By Route of Administration
16.7.2.2.4. By Distribution Channel
16.7.3. South Korea Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast, by Market Taxonomy
16.7.3.2.1. By Product
16.7.3.2.2. By Indication
16.7.3.2.3. By Route of Administration
16.7.3.2.4. By Distribution Channel
17. South Asia Analysis 2016 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Billion) Analysis Trend Analysis, by Market Taxonomy, 2016 to 2021
17.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Product
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Indication
17.4.4. By Route of Administration
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. India Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast, by Market Taxonomy
17.7.1.2.1. By Product
17.7.1.2.2. By Indication
17.7.1.2.3. By Route of Administration
17.7.1.2.4. By Distribution Channel
17.7.2. Indonesia Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast, by Market Taxonomy
17.7.2.2.1. By Product
17.7.2.2.2. By Indication
17.7.2.2.3. By Route of Administration
17.7.2.2.4. By Distribution Channel
17.7.3. Malaysia Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast, by Market Taxonomy
17.7.3.2.1. By Product
17.7.3.2.2. By Indication
17.7.3.2.3. By Route of Administration
17.7.3.2.4. By Distribution Channel
17.7.4. Thailand Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast, by Market Taxonomy
17.7.4.2.1. By Product
17.7.4.2.2. By Indication
17.7.4.2.3. By Route of Administration
17.7.4.2.4. By Distribution Channel
18. Oceania 2016 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Billion) Analysis Trend Analysis, by Market Taxonomy, 2016 to 2021
18.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Indication
18.4.4. By Route of Administration
18.4.5. By Distribution Channel
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. Australia Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast, by Market Taxonomy
18.7.1.2.1. By Product
18.7.1.2.2. By Indication
18.7.1.2.3. By Route of Administration
18.7.1.2.4. By Distribution Channel
18.7.2. New Zealand Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast, by Market Taxonomy
18.7.2.2.1. By Product
18.7.2.2.2. By Indication
18.7.2.2.3. By Route of Administration
18.7.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Analysis 2016 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Historical Market Size (US$ Billion) Analysis Trend Analysis, by Market Taxonomy, 2016 to 2021
19.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By Indication
19.3.4. By Route of Administration
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Product
19.4.2. By Indication
19.4.3. By Route of Administration
19.4.4. By Distribution Channel
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Country-Level Analysis & Forecast
19.7.1. GCC Countries Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast, by Market Taxonomy
19.7.1.2.1. By Product
19.7.1.2.2. By Indication
19.7.1.2.3. By Route of Administration
19.7.1.2.4. By Distribution Channel
19.7.2. Turkey Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast, by Market Taxonomy
19.7.2.2.1. By Product
19.7.2.2.2. By Indication
19.7.2.2.3. By Route of Administration
19.7.2.2.4. By Distribution Channel
19.7.3. South Africa Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast, by Market Taxonomy
19.7.3.2.1. By Product
19.7.3.2.2. By Indication
19.7.3.2.3. By Route of Administration
19.7.3.2.4. By Distribution Channel
19.7.4. North Africa Safety Needles Market
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast, by Market Taxonomy
19.7.5. By Product
19.7.6. By Indication
19.7.7. By Route of Administration
19.7.8. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis, by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Johnson & Johnson Services Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Key Financials
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.1.6.1. Marketing Strategy
21.3.1.6.2. Product Strategy
21.3.1.6.3. Channel Strategy
21.3.2. Sanofi
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Sales Footprint
21.3.2.4. Key Financials
21.3.2.5. SWOT Analysis
21.3.2.6. Strategy Overview
21.3.2.6.1. Marketing Strategy
21.3.2.6.2. Product Strategy
21.3.2.6.3. Channel Strategy
21.3.3. Dr. Reddy’s Laboratories
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Sales Footprint
21.3.3.4. Key Financials
21.3.3.5. SWOT Analysis
21.3.3.6. Strategy Overview
21.3.3.6.1. Marketing Strategy
21.3.3.6.2. Product Strategy
21.3.3.6.3. Channel Strategy
21.3.4. Bayer AG
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Sales Footprint
21.3.4.4. Key Financials
21.3.4.5. SWOT Analysis
21.3.4.6. Strategy Overview
21.3.4.6.1. Marketing Strategy
21.3.4.6.2. Product Strategy
21.3.4.6.3. Channel Strategy
21.3.5. Boehringer Ingelheim GmbH
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Sales Footprint
21.3.5.4. Key Financials
21.3.5.5. SWOT Analysis
21.3.5.6. Strategy Overview
21.3.5.6.1. Marketing Strategy
21.3.5.6.2. Product Strategy
21.3.5.6.3. Channel Strategy
21.3.6. Genentech Inc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Sales Footprint
21.3.6.4. Key Financials
21.3.6.5. SWOT Analysis
21.3.6.6. Strategy Overview
21.3.6.6.1. Marketing Strategy
21.3.6.6.2. Product Strategy
21.3.6.6.3. Channel Strategy
21.3.7. Eli Lilly and Company
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Sales Footprint
21.3.7.4. Key Financials
21.3.7.5. SWOT Analysis
21.3.7.6. Strategy Overview
21.3.7.6.1. Marketing Strategy
21.3.7.6.2. Product Strategy
21.3.7.6.3. Channel Strategy
21.3.8. The Medicines Company
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Sales Footprint
21.3.8.4. Key Financials
21.3.8.5. SWOT Analysis
21.3.8.6. Strategy Overview
21.3.8.6.1. Marketing Strategy
21.3.8.6.2. Product Strategy
21.3.8.6.3. Channel Strategy
21.3.9. Pfizer Inc.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Sales Footprint
21.3.9.4. Key Financials
21.3.9.5. SWOT Analysis
21.3.9.6. Strategy Overview
21.3.9.6.1. Marketing Strategy
21.3.9.6.2. Product Strategy
21.3.9.6.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Clot Busting Drugs Market
